PURPOSE OF REVIEW: Presence of antiphospholipid antibodies (aPL) is associated with unsuccessful pregnancy outcome. Based on an early concept of aPL-induced @entity49 and placental @entity715 , antithrombotic interventions have been used to reduce incidence of @entity2208 in @entity1701 ( @entity1701 ). The aim of this review is to summarize current knowledge on pathogenesis of @entity2208 in @entity1701 and the impact of different antithrombotic therapy strategies. RECENT FINDINGS: Pathogenetic concepts on @entity2208 in @entity1701 comprise aPL-mediated cell activation, disturbance of coagulation along with increased complement activation. There is increasing evidence that heparin exerts its effect by inhibiting complement activation rather than by its anticoagulation capacity. In this regard, the outcome of pregnancies in @entity1701 has considerably improved by the invention of therapies using combinations of @entity117 , unfractionated heparin (UFH) and/or low molecular weight heparin (LMWH). However, there is no clear evidence as to which treatment regimen should be preferred. Some studies indicate superiority of @entity117 plus heparin over @entity117 -only. Whether heparin-only treatment would confer equal effects and whether UFH and LMWH were of comparable efficacy currently is unknown. SUMMARY: Treatment with @entity117 and heparin decreases the risk of miscarriages in @entity1701 . Well designed trials as well as better @entity1 -at-risk profiling are warranted that identify which treatment strategy should be favored and whether detailed characterization of aPL specificities could help in individualizing therapy.

Heparin or XXXX or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2208 :: ('MESH:D000022', 'Disease') :: ['miscarriage'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity49 :: ('MESH:D019851', 'Disease') :: ['thrombophilia'] @entity1701 :: ('MESH:D016736', 'Disease') :: ['APS', 'antiphospholipid antibody syndrome'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity117 :: (MESH:D001241,Chemical) :: ['aspirin']
